160 related articles for article (PubMed ID: 22711372)
21. [Diagnosis of lung biopsy employing the 2015 WHO criteria and detection of related oncogenic driver mutations].
Fang F; Qiao XB; Yang L; Di J; Hu ST; Liu DG; Lyu N
Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):270-275. PubMed ID: 30955261
[No Abstract] [Full Text] [Related]
22. Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer.
Nizzoli R; Tiseo M; Gelsomino F; Bartolotti M; Majori M; Ferrari L; De Filippo M; Rindi G; Silini EM; Guazzi A; Ardizzoni A
J Thorac Oncol; 2011 Mar; 6(3):489-93. PubMed ID: 21258246
[TBL] [Abstract][Full Text] [Related]
23. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Mack PC; Holland WS; Burich RA; Sangha R; Solis LJ; Li Y; Beckett LA; Lara PN; Davies AM; Gandara DR
J Thorac Oncol; 2009 Dec; 4(12):1466-72. PubMed ID: 19884861
[TBL] [Abstract][Full Text] [Related]
24. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.
Santis G; Angell R; Nickless G; Quinn A; Herbert A; Cane P; Spicer J; Breen R; McLean E; Tobal K
PLoS One; 2011; 6(9):e25191. PubMed ID: 21949883
[TBL] [Abstract][Full Text] [Related]
25. [Novel morphological and molecular aspects of lung cancer].
Warth A; Stenzinger A; Weichert W
Pathologe; 2013 Sep; 34(5):419-28. PubMed ID: 23900599
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples.
Bozzetti C; Negri FV; Azzoni C; Naldi N; Nizzoli R; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Silini EM; Ardizzoni A
Diagn Cytopathol; 2013 Jul; 41(7):595-8. PubMed ID: 22833420
[TBL] [Abstract][Full Text] [Related]
27. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
28. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens.
Billah S; Stewart J; Staerkel G; Chen S; Gong Y; Guo M
Cancer Cytopathol; 2011 Apr; 119(2):111-7. PubMed ID: 21400670
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
Takahashi T; Sonobe M; Kobayashi M; Yoshizawa A; Menju T; Nakayama E; Mino N; Iwakiri S; Sato K; Miyahara R; Okubo K; Manabe T; Date H
Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
[TBL] [Abstract][Full Text] [Related]
30. A decade of advances in treatment for advanced non-small cell lung cancer.
Gettinger S; Lynch T
Clin Chest Med; 2011 Dec; 32(4):839-51. PubMed ID: 22054890
[TBL] [Abstract][Full Text] [Related]
31. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.
Forest F; Stachowicz ML; Casteillo F; Karpathiou G; Gouzy-Grosjean F; Guilaubey C; Cottier M; Beal J; Clemenson A; Péoc'h M
Exp Mol Pathol; 2017 Dec; 103(3):306-310. PubMed ID: 29175303
[TBL] [Abstract][Full Text] [Related]
32. Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.
Wu JY; Yang CH; Hsu YC; Yu CJ; Chang SH; Shih JY; Yang PC
Clin Lung Cancer; 2010 Jul; 11(4):257-63. PubMed ID: 20630828
[TBL] [Abstract][Full Text] [Related]
33. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Zappa F; Droege C; Betticher D; von Moos R; Bubendorf L; Ochsenbein A; Gautschi O; Oppliger Leibundgut E; Froesch P; Stahel R; Hess T; Rauch D; Schmid P; Mayer M; Crowe S; Brauchli P; Ribi K; Pless M;
Lung Cancer; 2012 Dec; 78(3):239-44. PubMed ID: 23009726
[TBL] [Abstract][Full Text] [Related]
34. Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.
Chen YT; Chang JW; Liu HP; Yu TF; Chiu YT; Hsieh JJ; Chen YT; Chen YR; Wu HD; Huang SF
J Thorac Oncol; 2011 Dec; 6(12):2027-35. PubMed ID: 22052229
[TBL] [Abstract][Full Text] [Related]
35. Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis.
Solomon SB; Zakowski MF; Pao W; Thornton RH; Ladanyi M; Kris MG; Rusch VW; Rizvi NA
AJR Am J Roentgenol; 2010 Jan; 194(1):266-9. PubMed ID: 20028932
[TBL] [Abstract][Full Text] [Related]
36. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
37. Can cytology reliably subtype non-small cell lung carcinomas?
Jain D; Bubendorf L
Cytopathology; 2022 Jan; 33(1):8-13. PubMed ID: 34494327
[TBL] [Abstract][Full Text] [Related]
38. Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes.
Lozano MD; Zulueta JJ; Echeveste JI; Gúrpide A; Seijo LM; Martín-Algarra S; Del Barrio A; Pio R; Idoate MA; Labiano T; Perez-Gracia JL
Oncologist; 2011; 16(6):877-85. PubMed ID: 21572125
[TBL] [Abstract][Full Text] [Related]
39. Outsourcing cytological samples to a referral laboratory for EGFR testing in non-small cell lung cancer: does theory meet practice?
Vigliar E; Malapelle U; Bellevicine C; de Luca C; Troncone G
Cytopathology; 2015 Oct; 26(5):312-7. PubMed ID: 25376259
[TBL] [Abstract][Full Text] [Related]
40. [Morphological and molecular pathology of lung cancer].
Petersen I
Pathologe; 2010 Oct; 31 Suppl 2():204-10. PubMed ID: 20852864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
